On May 28, 2025 Thermo Fisher Scientific, the world leader in serving science, reported it will showcase some of the technologies that have helped power precision oncology at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Thermo Fisher Scientific, MAY 28, 2025, View Source [SID1234653466]). Through poster presentations, abstracts, and an end-to-end presence across oncology diagnostics, clinical trials, and drug development, Thermo Fisher will demonstrate how its integrated solutions – from biomarker discovery to commercialization – are improving access to targeted cancer therapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
By advancing NGS technologies that prioritize speed, accuracy, and accessibility, the company, through its clinical sequencing business, is helping to ensure that patients in all care settings benefit from the latest innovations. This year marks a significant milestone for Thermo Fisher: a decade of pharma partnership in NGS companion diagnostics development and commercialization, supporting new drug launches globally with decentralized in-country CDx solution.
This commitment extends to its clinical research capabilities. Over the past five years, Thermo Fisher has supported more than 750 hematology and oncology clinical trials, involving over 175,000 patients at more than 35,000 sites in over 100 countries. Through its PPD clinical research business, the company takes a patient-centered approach to trial design and execution, ensuring that studies are not only scientifically rigorous but also more accessible and inclusive.
"Reflecting on the last decade of partnership with pharmaceutical companies and their therapeutic innovations, we’re proud to continue our legacy as a trusted partner and celebrate the impact these collaborations have had on expanding access to precision cancer care," said Kathy Davy, president of Clinical Next-Generation Sequencing at Thermo Fisher Scientific. "Behind every test is a patient waiting for answers. That’s what drives us – equipping clinicians with fast, reliable insights so they can make confident, timely treatment decisions that change lives."
Davy will deliver opening remarks at the Canadian Evening at ASCO (Free ASCO Whitepaper) 2025, hosted by Breast Cancer Canada. Held Friday, May 30, at the Marriott Marquis Chicago, this event brings together researchers, clinicians, advocates, and industry leaders to celebrate progress in cancer research.
Research and Abstract Highlights at ASCO (Free ASCO Whitepaper) 2025
At ASCO (Free ASCO Whitepaper) 2025, researchers from Thermo Fisher and its customers will present new data on precision oncology, including:
Assessment of Homologous Recombination Deficiency and BRCA Status (Abstract 3130, Poster presentation) – evaluates a decentralized NGS assay for identifying HRD and BRCA mutations in ovarian cancer.
Combined Genomic Profiling of cfDNA and ctDNA – demonstrates how dual analysis of cfDNA and ctcDNA using a prostate cancer-specific panel can provide complementary molecular insights.
Association between Targeted Therapy and Survival in Patients with AML (Abstract e23283 in collaboration with EVERSANA) – analyzes real-world data showing improved survival in high-risk MDS patients receiving targeted therapies based on genetic mutations.
Attendees can connect with Thermo Fisher experts at booth #12049 to learn more about how the company supports oncology programs from research through commercialization.